Canadian radioisotope developer MDS Nordion of Kanata, Ontario, is expanding the range of services it offers to include drug discovery and development.
The services are targeted at biotechnology companies that are developing pharmaceuticals that include a radionuclide component, according to the company. By contracting with MDS Nordion, biotech firms might be able to get drugs to market faster than if they had to build a capability themselves, according to the company.
The new services include:
- Customized radiolabeling and radioconjugation method development, validation, and characterization
- In vitro and in vivo biological characterization
- Preclinical development services
MDS Nordion already offers contract manufacturing services to drug companies, and the new service is a natural expansion of its services to a point earlier in the product development cycle, the company said.
By AuntMinnie.com staff writers
June 28, 2005
Related Reading
MDS Nordion brings Cu-64 to market, June 16, 2005
MDS Nordion, Macrocyclics sign R&D accord, May 26, 2005
MDS hires Hawkins as chief science and technology officer, April 28, 2005
Declining U.S. dollar hurts MDS Life Sciences' Q1, March 11, 2005
MDS Nordion developing external-beam RT system, September 30, 2004
Copyright © 2005 AuntMinnie.com
